AbbVie's Q3 2025 earnings are in. Skyrizi is on fire, neuroscience is booming, but Botox is a bust. Get the summary.

Patients with refractory Crohn’s disease who previously received ustekinumab experienced clinical and endoscopic improvements ...

These stocks aren't popular right now, but their strong underlying businesses make them hot deals to pounce on.

For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...

The pharma company's newer immunology drugs, Skyrizi and Rinvoq, have delivered robust sales growth that's proving to be the ...

Skyrizi and Rinvoq sold nearly seven billion dollars, almost half of the company’s income for the quarter alone.

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...

(Reuters) -AbbVie said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...

After Rinvoq won two new indications in as many months, AbbVie's immunology compatriot Skyrizi is getting in on the approval action. Skyrizi clinched a second nod, this time to treat adults with ...

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe "We know many people living with psoriasis are looking for ...

AbbVie ABBV announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat adults with moderately to severely active ulcerative colitis (UC) in the United States. Skyrizi’s ...